Cerebral small vessel disease: targeting oxidative stress as a novel therapeutic strategy?

De Silva, T. M. and Miller, A. A. (2016) Cerebral small vessel disease: targeting oxidative stress as a novel therapeutic strategy? Frontiers in Pharmacology, 7, 61. (doi: 10.3389/fphar.2016.00061) (PMID:27014073) (PMCID:PMC4794483)

[img]
Preview
Text
135043.pdf - Published Version
Available under License Creative Commons Attribution.

407kB

Abstract

Cerebral small vessel disease (SVD) is a major contributor to stroke, and a leading cause of cognitive impairment and dementia. Despite the devastating effects of cerebral SVD, the pathogenesis of cerebral SVD is still not completely understood. Moreover, there are no specific pharmacological strategies for its prevention or treatment. Cerebral SVD is characterized by marked functional and structural abnormalities of the cerebral microcirculation. The clinical manifestations of these pathological changes include lacunar infarcts, white matter hyperintensities, and cerebral microbleeds. The main purpose of this review is to discuss evidence implicating oxidative stress in the arteriopathy of both non-amyloid and amyloid (cerebral amyloid angiopathy) forms of cerebral SVD and its most important risk factors (hypertension and aging), as well as its contribution to cerebral SVD-related brain injury and cognitive impairment. We also highlight current evidence of the involvement of the NADPH oxidases in the development of oxidative stress, enzymes that are a major source of reactive oxygen species in the cerebral vasculature. Lastly, we discuss potential pharmacological strategies for oxidative stress in cerebral SVD, including some of the historical and emerging NADPH oxidase inhibitors.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Miller, Dr Alyson
Authors: De Silva, T. M., and Miller, A. A.
College/School:College of Medical Veterinary and Life Sciences > Institute of Cardiovascular and Medical Sciences
Journal Name:Frontiers in Pharmacology
Publisher:Frontiers Media
ISSN:1663-9812
ISSN (Online):1663-9812
Copyright Holders:Copyright © 2016 The Authors
First Published:First published in Frontiers in Pharmacology 7:61
Publisher Policy:Reproduced under a Creative Commons License

University Staff: Request a correction | Enlighten Editors: Update this record